[
    [
        {
            "time": "",
            "original_text": "智飞生物新冠疫苗关键数据出炉 具备安全性可开展III期临床实验",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "III期临床",
                    "安全性"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物新冠疫苗关键数据出炉 具备安全性可开展III期临床实验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医疗健康-基金3Q分析：三季度医药板块配置比例同比上升 环比下降",
            "features": {
                "keywords": [
                    "医疗健康",
                    "基金",
                    "医药板块",
                    "配置比例",
                    "同比上升",
                    "环比下降"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医疗健康-基金3Q分析：三季度医药板块配置比例同比上升 环比下降",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物重组新冠疫苗三期筹备中，一二期未发现严重不良事件",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "III期筹备",
                    "严重不良事件"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物重组新冠疫苗三期筹备中，一二期未发现严重不良事件",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "中国研发新冠病毒重组亚单位疫苗完成二期临床",
            "features": {
                "keywords": [
                    "中国",
                    "新冠疫苗",
                    "重组亚单位",
                    "二期临床"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中国研发新冠病毒重组亚单位疫苗完成二期临床",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物新冠疫苗将进三期临床试验 ST电能前三季扭亏为盈",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "III期临床",
                    "ST电能",
                    "扭亏为盈"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药",
                    "能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物新冠疫苗将进三期临床试验 ST电能前三季扭亏为盈",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "人民金融·创新药指数涨0.9% 智飞生物新冠疫苗获进展",
            "features": {
                "keywords": [
                    "创新药指数",
                    "智飞生物",
                    "新冠疫苗",
                    "进展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "人民金融·创新药指数涨0.9% 智飞生物新冠疫苗获进展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物合作研发新冠疫苗将进入Ⅲ期临床试验",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "III期临床"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物合作研发新冠疫苗将进入Ⅲ期临床试验",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        }
    ]
]